No full text
Article (Scientific journals)
Successful treatment of progressive mucocutaneous infection due to acyclovir- and foscarnet-resistant herpes simplex virus with (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC).
Snoeck, R.; Andrei, G.; Gerard, Marie-Christine et al.
1994In Clinical Infectious Diseases, 18 (4), p. 570-8
Peer Reviewed verified by ORBi
 

Files


Full Text
No document available.

Send to



Details



Keywords :
AIDS-Related Opportunistic Infections/complications/drug therapy; Acyclovir/pharmacology; Administration, Topical; Adult; Antiviral Agents/administration & dosage/therapeutic use; Cytosine/administration & dosage/analogs & derivatives/therapeutic use; DNA Restriction Enzymes; DNA, Viral/genetics; Drug Resistance, Microbial; Foscarnet/pharmacology; Herpes Genitalis/complications/drug therapy; Herpes Simplex/complications/drug therapy; Herpesvirus 1, Human/drug effects/enzymology/genetics; Herpesvirus 2, Human/drug effects/enzymology/genetics; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive/complications; Male; Opportunistic Infections/complications/drug therapy; Organophosphorus Compounds/administration & dosage/therapeutic use; Phosphonic Acids; Skin Diseases, Viral/complications/drug therapy; Thymidine Kinase/antagonists & inhibitors
Abstract :
[en] The acyclic nucleoside phosphonate (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC) was used topically for the treatment of persistent mucocutaneous infections in two cases. One patient with AIDS suffered from a perineal lesion due to infection with herpes simplex virus type 2 (HSV-2) and did not respond to acyclovir and was intolerant of foscarnet. A bone marrow transplant recipient developed orofacial lesions due to infection with herpes simplex virus type 1 (HSV-1) that failed to respond to therapy with both acyclovir and foscarnet. After topical application of HPMPC, the HSV-2 lesions completely resolved. However, the lesions recurred 3 weeks later, and, upon subsequent treatment with HPMPC, regressed. On recurrence, the virus was found to be sensitive to acyclovir, which the patient was given. Again HSV-2, which was resistant to acyclovir, emerged; similar observations were made after another cycle of HPMPC therapy. The HSV-1 isolates were resistant to acyclovir and foscarnet. Following local HPMPC treatment, the lesions regressed, but after 1 week, a second course of topical HPMPC therapy had to be instituted for recurrent infection. The lesions again regressed, and as the recurrent virus was sensitive to acyclovir, the patient was successfully treated with the drug. The results of this study point to the potential usefulness of topical HPMPC in the treatment of immunocompromised patients with HSV-related mucocutaneous infections that are refractory to therapy with acyclovir and/or foscarnet.
Disciplines :
Immunology & infectious disease
Author, co-author :
Snoeck, R.
Andrei, G.
Gerard, Marie-Christine ;  Centre Hospitalier Universitaire de Liège - CHU > Imagerie médicale
Silverman, A.
Hedderman, A.
Balzarini, J.
Sadzot-Delvaux, Catherine ;  Université de Liège - ULiège > Département des sciences de la vie > GIGA-R : Virologie et immunologie - GIGA-M : Coordination scientifique
Tricot, G.
Clumeck, N.
De Clercq, E.
Language :
English
Title :
Successful treatment of progressive mucocutaneous infection due to acyclovir- and foscarnet-resistant herpes simplex virus with (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC).
Publication date :
1994
Journal title :
Clinical Infectious Diseases
ISSN :
1058-4838
eISSN :
1537-6591
Publisher :
Univ Chicago Press, Chicago, United States - Illinois
Volume :
18
Issue :
4
Pages :
570-8
Peer reviewed :
Peer Reviewed verified by ORBi
Available on ORBi :
since 25 November 2009

Statistics


Number of views
46 (1 by ULiège)
Number of downloads
0 (0 by ULiège)

Scopus citations®
 
164
Scopus citations®
without self-citations
129
OpenCitations
 
132

Bibliography


Similar publications



Contact ORBi